I have been writing a lot about the upcoming American Society of Hematologists (ASH) annual meeting on our other daily site, http://www.multiplemyelomablog.com/.
The conference/meetings, which start Friday in Orlando, Florida, is the largest gathering of hematologists in the world each year.
“So what?” you might ask. Well, this is a really big deal for patients dealing with leukemia, lymphoma, multiple myeloma and a number of other lesser known blood cancers.
I attended my first ASH last year in New Orleans and was amazed by the event. Here is a link to one of the many stories I wrote for Help With Cancer.org last year: http://www.helpwithcancer.org/2009/12/good-morning-from-ash-how-exciting-lets.html.
Drug companies, researchers and hematologists try and time the release of their biggest, most promising studies at ASH each year. 2009 was a “blockbuster” year in the world of multiple myeloma research–but not so much for leukemia and lymphoma. Here is another link to a story I wrote about that:
Later there were several important and promising research studies presented, including this one from an Italian study about how nilotinib, which is marketed as Tasigna, outpreformed Gleevec in chronic myeloid leukemia patients: http://www.helpwithcancer.org/2009/12/here-comes-good-news-we-were-expecting.html.
So what about this year? A couple of things. Yesterday I wrote an article about the basics about how to interpret ASH related press releases and research study results: http://multiplemyelomablog.blogspot.com/2010/11/what-multiple-myleloma-patients-should.html.
Reviewing yesterday’s article might make it easier to interpret this pre-ASH press release about Pfizer’s stable of leukemia, lymphoma and new multiple myeloma drugs:
Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology
Company to Present Phase 3 Data Studying Bosutinib in Chronic Myeloid Leukemia
Pfizer to Initiate Phase 3 Study of Inotuzumab Ozogamicin in Combination with Rituximab in Patients with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma in 2011
NEW YORK, Nov. 29, 2010 /PRNewswire- Pfizer (NYSE: PFE) said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Key highlights include results from a Phase 3 study, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study, involving bosutinib for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).(1) The company will also present Phase 2 data from inotuzumab ozogamicin (CMC-544) for the treatment of B-cell Non-Hodgkin lymphoma (NHL).(2) These presentations underscore the company’s commitment to advancing new treatments for patients living with various hematologic malignancies, which represent the second leading cause of cancer death.(3)
Pfizer also announced that it would initiate an open-label, randomized, Phase 3 study, Study B1931008, of inotuzumab ozogamicin administered in combination with rituximab compared to defined investigator’s choice therapy in subjects with relapsed or refractory CD22-positive aggressive NHL who are not candidates for intensive high-dose chemotherapy.(4) This study will be open and enrolling in early 2011.
Here is a link back to the release if you would like more detail: Pfizer to Present Data from Its Hematology Portfolio at ASH.
I will be leaving for Orlando Thursday morning for two pre-conference meetings. Official news begins to be released on Friday.
I will be posting non-multiple myeloma related news here all weekend. Watch for my twice daily reports starting Friday.
I had better rest up–I was over in Orlando scouting the venue on Sunday and it is massive! I see lots of walking in my future.
Feel good and keep smiling! Pat